Xenetic Biosciences (XBIO) investor relations material

Executive summary

• Advanced DNase-based immuno-oncology technology targeting NETs in difficult-to-treat cancers, with focus on preclinical and translational data supporting therapeutic potential.

• Progressed investigator-initiated studies in Israel, including ongoing PDAC and proposed LBCL studies, and advanced toward IND-enabling activities for DNase I.

• Strategic focus on collaborations and maximizing shareholder value through potential alternatives.

Financial highlights

• Net loss for 2025 was approximately $2.7 million, reflecting continued investment in scientific programs.

• Royalty revenue increased 19% year-over-year to $3.0 million, primarily from Takeda sublicense payments.

• Research and development expenses decreased 7% to $3.1 million, with prior year including a $0.7 million impairment charge not repeated in 2025.

• General and administrative expenses fell 20% to $2.7 million, mainly due to prior year severance costs.

• Ended 2025 with $7.9 million in cash, up $1.7 million from prior year, mainly from a $4.0 million public offering.

Outlook and guidance

• Focus remains on advancing DNase-based technology into Phase 1 clinical development for pancreatic carcinoma and other solid tumors.

• Ongoing translational and manufacturing activities are informed by recent preclinical data, with IND submission targeted.

• Strategic alternatives under review to enhance shareholder value.